04/07/2017 17:00:14

NeuroSearch and Saniona enter into agreement on transfer of rights

Related content
31 Aug - 
NeuroSearch A/S – H1 report 2017
21 Mar - 
Report on Annual General Meeting of NeuroSearch A/S
07 Mar - 
Report pursuant to section 28a of the Danish Act on Sec..
Related debate
30 Aug - 
Mon Halvårsregnskabet fra Neurosearch bringer nyt? Noge..

Company announcement

4 July 2017

NeuroSearch announces that it has sold to Saniona A/S its remaining rights in the preclinical and clinical assets which NeuroSearch divested to Saniona during the period 2012-2016. In full and final settlement of NeuroSearch’s remaining rights in the divested programs, NeuroSearch will receive from Saniona a one-time cash payment of DKK 5.5 million. Furthermore, Saniona will fully assume NeuroSearch’s royalty obligations to third parties regarding potential net sales of products, including NeuroSearch’s royalty payment obligations to Boehringer Ingelheim on tesofensine and to GlaxoSmithKline on NS2359.

In August 2012, NeuroSearch sold its technology platform including patents and data in relation to 15 preclinical and clinical programs to Saniona. In October 2014, the rights to NeuroSearch’s clinical development compounds, tesofensine and NS2359, were divested to Saniona. In May 2016, NeuroSearch divested its rights to the remaining projects and compounds, including the clinical development compounds ACR325 and ACR343, to Saniona.

Of the DKK 5.5 million received, NeuroSearch will pay DKK 0.4 million in total to Boehringer Ingelheim and GlaxoSmithKline. The remaining DKK 5.1 million will add DKK 2.2 million to our operating income, and the remaining DKK 2.9 million will be added to discontinued operations.

NeuroSearch still has potential milestone payments from TEVA totalling up to DKK 55 million if Huntexil® is granted market approval.

The conclusion of this agreement follows NeuroSearch’s announced strategy to dispose of all remaining assets in the best possible way.

Outlook for 2017

For 2017, NeuroSearch now expects an operating loss in the range of DKK 2.3-3.3 million, against previously DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any further income from the possible sale of Company assets or other potential income from the Company's agreement with Teva.

Contact

Allan Andersen, CEO, mobile +45 4016 3864.

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.

 

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Net Asset Value(s)

23/10/2017 13:14:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 20 October 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.5p -       including income, 787.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Rathbones : Form 8.3 - [Clinigen Group PLC]

23/10/2017 10:58:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Rathbone Brothers PLC (b) Owner or controller of ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants
2
Sequent Announces Two New Sequent Platform Versions
3
Simmons Reports Third Quarter 2017 Earnings
4
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
5
MEDIA ADVISORY: US Commerce Secretary Wilbur Ross to Hold Listening Session at National Minority Supplier Development Council Annual Conference

Related stock quotes

NeuroSearch A/S 3.54 0.9% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2017 18:06:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171023.1 - EUROWEB7 - 2017-10-23 19:06:31 - 2017-10-23 18:06:31 - 1000 - Website: OKAY